What happened with UTMD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Utah Medical Products makes devices used in women’s healthcare, childbirth and neonatal intensive care. Gynecology, electrosurgery and urology products together generate most of its revenue. A major product is the Filshie Clip System, which closes the fallopian tubes for permanent female contraception. It also makes blood-pressure monitoring devices, including Deltran kits, and other specialty devices for hospitals and outpatient practices.
Healthcare facilities pay the company directly in the United States and selected overseas markets; distributors buy its devices for resale elsewhere. Other companies also pay it to manufacture components and finished devices for their own product lines. Its indirect overseas sales depend heavily on a small group of distributors, including a major distributor of Deltran kits in China.
Sales depend on clinicians choosing its devices and hospital purchasing policies allowing access to them. Long-term supply contracts and restrictions on clinicians’ role in purchasing can make adoption harder. Regulatory approval also limits where products can be supplied: approval for Irish-made Filshie clips remains pending in the European Union, where Femcare has retained inventory from its former UK manufacturer to serve demand.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Utah Medical Products’ results hinge on demand for specialty women’s-health devices, including Filshie clips, and overseas distributor orders, after its major relationship supplying devices to PendoTECH ended in 2025.
ICU Medical competes for hospitals’ monitoring purchases with Utah Medical Products: its products that monitor blood circulation overlap with UTMD’s disposable blood-pressure sensors and monitoring kits. Watch ICU Medical’s hemodynamic-monitoring products, rather than its broader infusion business, for competition facing UTMD’s blood-pressure monitoring revenue.
Merit Medical Systems competes with Utah Medical Products for hospital and medical-device manufacturer business in pressure-sensing components and procedural products; both also supply parts and finished devices for other manufacturers’ product lines. Merit’s sales of those parts and devices—its OEM business—are the line to watch alongside UTMD’s own manufacturing sales to other companies.
Utah Medical Products Inc earningsThis company
Utah Medical Products’ report will show whether hospital and clinic purchases of its women’s health, neonatal and blood-pressure devices can offset pressure on blood-pressure sales and sustain gross margin.
Read sales by product line alongside gross margin. Stronger gynecology and neonatal sales with a steady margin would show those products are sustaining the economics of manufacturing; further declines in blood-pressure products alongside a falling margin would show other lines have not filled the gap.
Merit Medical Systems Inc earningsMMSI
Merit Medical Systems’ report will show whether hospitals and device makers are buying pressure-sensing components and procedural products—demand that also supports the hospital business and OEM orders Utah Medical Products pursues.
Read Merit Medical Systems’ OEM sales alongside its pressure-sensing and procedural-product sales. Strength in both would show that device makers and hospitals are still ordering, supporting the demand Utah Medical Products pursues for OEM work and hospital business; weaker OEM sales would point to less support for UTMD’s OEM channel, not prove how UTMD itself performed.
ICU Medical Inc earningsICUI
ICU Medical’s report will show how hospital purchases of its hemodynamic-monitoring products are changing; those products compete with Utah Medical Products’ disposable blood-pressure sensors and monitoring kits for hospital orders.
Focus on ICU Medical’s hemodynamic-monitoring products, not its infusion business. Rising sales would show hospitals are buying monitoring products, but ICU Medical may also be winning orders UTMD could pursue; falling sales would suggest softer demand in this category, not an automatic benefit for UTMD.
